查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493354

美國血液診斷市場規模、佔有率、趨勢分析報告：按產品類型、按測試類型、按最終用途、按地區、細分市場預測，2024-2030 年

U.S. Hematology Diagnostics Market Size, Share & Trends Analysis Report By Product (Instrument, Consumable), By Test Type, By End-use (Hospital, Diagnostic Lab), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10個工作天內

價格

美國血液診斷市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，美國血液診斷市場規模預計將達到30.7億美元，2024年至2030年複合年成長率為5.3%。

癌症盛行率的增加是市場成長的主要因素之一。根據美國癌症協會統計，2021年有超過190萬人新診斷出癌症，同年有超過60萬人死於癌症。因此，癌症診斷藥物的需求預計將擴大。

此外，技術進步徹底改變了血液檢測系統，使檢測變得更簡單，減輕了患者的痛苦。隨著血液相關疾病的研發投資不斷增加，血液診斷的未來性充滿希望。由於醫療保健支出的增加和對提高診斷能力的日益關注，預計血液診斷市場在預測期內將顯著成長。

血液相關疾病盛行率的上升是支持美國血液診斷市場成長的關鍵因素。這個市場擴張主要是由新興研究工作推動的，這些研究工作探索血液學診斷在早期檢測各種類型癌症中的有效性。根據白血病和淋巴瘤協會估計，2023年將有約59,610人被診斷出患有白血病，美國報告的白血病新病例約為1,958,310例。

美國血液診斷市場報告亮點：

  • 按產品分類，預計到 2023 年，消耗品將以 65% 左右的佔有率主導市場，並在預測期內實現最快的複合年成長率。血液診斷耗材是診斷實驗室和醫療機構日常業務的關鍵組成部分。這些耗材對於執行對患者護理至關重要的各種血液學測試和程序至關重要。
  • 按測試類型分類，白血球 (WBC) 測試領域預計將在 2023 年佔據最大的市場佔有率，並在預測期內實現最快的複合年成長率。市場對白血球 (WBC) 檢測的需求主要是由於需要準確、快速地評估白血球計數和分類計數。該測試在美國市場的各種醫療狀況的診斷和監測中發揮著重要作用，並已成為臨床實踐中的標準做法。
  • 按最終用途分類，醫院細分市場將在 2023 年佔據主導地位。另一方面，診斷實驗室領域預計在預測期內將以最快的複合年成長率成長。血液檢測實驗室為診斷和管理血液疾病、感染疾病和其他健康狀況提供準確可靠的結果，在醫療保健中發揮重要作用。它可以幫助醫療保健提供者根據測試結果做出有關患者護理的明智決策。所有因素都可能推動該細分市場的成長。
  • 2021 年，Illumina 推出了 TruSight Hematology Panel，次世代定序儀(NGS) 面板。這種創新的解決方案可實現全面的基因分析，為診斷和治療提供寶貴的見解。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國血液診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 美國血液診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國血液診斷市場：產品預估及趨勢分析

  • 2023年及2030年產品市場佔有率
  • 細分儀表板
  • 美國血液診斷市場的產品展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 裝置
  • 消耗品

第5章美國血液診斷市場：測試類型估計和趨勢分析

  • 2023 年和 2030 年測試類型市場佔有率
  • 細分儀表板
  • 按測試類型分類的美國血液診斷市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 白血球測試
  • 紅血球測試
  • 血紅素測試
  • 血球容積比測試
  • 血小板功能

第6章美國血液診斷市場：最終用途估計與趨勢分析

  • 2023 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 按最終用途分類的美國血液診斷市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 醫院
  • 診斷實驗室
  • 其他

第7章美國血液診斷市場：區域估計與趨勢分析

  • 2023 年和 2030 年按地區分類的市場佔有率佔有率
  • 美國血液診斷市場按地區前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 西
  • 中西部
  • 東北
  • 西南
  • 東南

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
  • 公司簡介
    • Abbott
    • Beckman Coulter
    • Sysmex Corporation
    • Horiba
    • Bio-Rad Laboratories
    • Siemens Healthcare
    • F. Hoffmann-La Roche Ltd.
    • Mindray
    • Nihon Kohden
    • EKF Diagnostics
Product Code: GVR-4-68040-284-4

U.S. Hematology Diagnostics Market Growth & Trends:

The U.S. hematology diagnostics market size is anticipated to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer is one of the primary factors contributing to the market growth. According to the American Cancer Society, Inc., in 2021, over 1.9 million new cancer cases were diagnosed, and over 600,000 people died from cancer in the same year. Hence, the demand for cancer diagnostics is expected to grow.

In addition, technological advancements have revolutionized blood testing systems, making them simpler and less painful for patients. The future of hematology diagnostics looks promising owing to increased investments in research and development focused on blood-related diseases. With rising healthcare expenditure and a growing focus on improving diagnostic capabilities, the market for hematology diagnostics is expected to experience significant growth in the forecast period.

The rising prevalence of blood-related conditions is a significant driver behind the growth of the hematology diagnostics market in the U.S. Expansion in this market is predominantly propelled by emerging research endeavors exploring the effectiveness of hematology diagnostics in the early identification of different types of cancers. According to estimates from the Leukemia & Lymphoma Society, in 2023, about 59,610 people are expected to be diagnosed with leukemia, and about 1,958,310 new cases of leukemia were reported in the U.S.

U.S. Hematology Diagnostics Market Report Highlights:

  • Based on product, consumables dominated the market with a share of around 65% in 2023 and are expected to register the fastest CAGR during the forecast period. Hematology diagnostic consumables are indeed crucial components in the daily functions of diagnostic labs and healthcare facilities. These consumables are integral to conducting various hematology tests and procedures essential for patient care
  • Based on test type, the white blood cell (WBC) test segment accounted for the largest market share in 2023 and is expected to register the fastest CAGR during the forecast period. The demand for White Blood Cell (WBC) testing in the market is primarily fueled by the need for precise and prompt evaluation of white and differential counts. This testing is a standard practice in clinical settings as it plays a crucial role in diagnosing and monitoring a wide range of medical conditions in the U.S. market
  • Based on end-use, the hospitals segment dominated the market in 2023. On the other hand, the diagnostic labs segment is projected to grow at the fastest CAGR over the forecast period. Blood testing laboratories play a vital role in healthcare by providing accurate and reliable results for diagnosing and managing blood disorders, infections, and other health conditions. They help healthcare providers make informed decisions about patient care based on the test results. All factors would drive the market segment's growth
  • In 2021, Illumina launched the TruSight Hematology Panel, a next-generation sequencing (NGS) panel designed to detect hematological disorders. This innovative solution enables comprehensive genetic analysis, providing valuable insights for diagnosis and treatment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Instrument
    • 1.2.3. Test Type
    • 1.2.4. End-use
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product
    • 2.2.2. Instrument
    • 2.2.3. Test Type
    • 2.2.4. End-use
  • 2.3. Competitive Insights

Chapter 3. U.S. Hematology Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Hematology Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Hematology Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Hematology Diagnostics Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Instruments
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Hematology Analyzers
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.2. Clinical Laboratory Testing Hematology Analyzers
      • 4.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.2.2. Point-Of-Care Testing Hematology Analyzers
      • 4.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Flow Cytometers
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Slide Stainers/Markers
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Consumables
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Reagents
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Stains
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. Controls and Calibrators
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Hematology Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Test Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Hematology Diagnostics Market by Test Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. White Blood Cells (WBC) Test
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Red Blood Cells (RBC) Test
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Hemoglobin Test
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Hematocrit Test
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Platelet Function
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Hematology Diagnostics Market: End-use Estimates & Trend Analysis

  • 6.1. End-use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Hematology Diagnostics Market by End-use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Hospitals
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Diagnostic Labs
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Hematology Diagnostics Market: Region Estimates & Trend Analysis

  • 7.1. Regional Market Share, 2023 & 2030
  • 7.2. U.S. Hematology Diagnostics Market by Region Outlook
  • 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 7.3.1. West
      • 7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Midwest
      • 7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Northeast
      • 7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Southwest
      • 7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.5. Southeast
      • 7.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Abbott
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Beckman Coulter
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Sysmex Corporation
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Horiba
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Bio-Rad Laboratories
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Siemens Healthcare
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. F. Hoffmann-La Roche Ltd.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Mindray
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Nihon Kohden
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. EKF Diagnostics
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. hematology diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 3 U.S. hematology diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 U.S. hematology diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 U.S. hematology diagnostics market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. hematology diagnostics market outlook
  • Fig. 9 Hematology diagnostics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. hematology diagnostics market driver impact
  • Fig. 14 U.S. hematology diagnostics market restraint impact
  • Fig. 15 U.S. hematology diagnostics market: Product movement analysis
  • Fig. 16 U.S. hematology diagnostics market: Product outlook and key takeaways
  • Fig. 17 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Consumables estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. hematology diagnostics market: Test type movement Analysis
  • Fig. 20 U.S. hematology diagnostics market: Test type outlook and key takeaways
  • Fig. 21 White blood cells (WBC) test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Red blood cells (RBC) test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Hemoglobin test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Hematocrit test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Platelet function market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. hematology diagnostics market: End-use movement Analysis
  • Fig. 27 U.S. hematology diagnostics market: End-use outlook and key takeaways
  • Fig. 28 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Diagnostic labs test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. hematology diagnostics market: Regional movement analysis
  • Fig. 32 U.S. hematology diagnostics market: Regional outlook and key takeaways
  • Fig. 33 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)